Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
NCT ID: NCT06456736
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
200 participants
OBSERVATIONAL
2024-06-30
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Risk Prediction Model for Severe Autoimmune Encephalitis
NCT06697678
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
NCT05711563
Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China
NCT02561260
A Multicentric Cohort of Autoimmune Encephalitis
NCT06760091
HLA Analysis in Autoimmune Encephalitis and Related Disorders
NCT04106596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
None, non-interventional study
Not applicable, non-interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 15 years
* Admission to an adult ICU during the course of the disease
Exclusion Criteria
* ICU length of stay of 24 hours or less.
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lixia Qin
Principal Investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Xiangya_critical AE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.